Forbion-backed biotech raises $138M to develop ALS drug

November 14, 2023

Netherlands-based biotechnology company VectorY Therapeutics has raised 129 million euros, or $138 million, to fund development of brain disease drugs. The Series A financing, announced Monday, was co-led by venture capital firm Forbion and European investor EQT Life Sciences, alongside […]

Childhood Vaccine Exemptons Hit Highest Level Yet: CDC

November 10, 2023

Category: Industry, Vaccines

In a sign that suggests many American parents have become dubious about the safety of childhood vaccines, new government data shows that immunization exemptions for kindergartners have reached their highest levels ever. The latest statistics continue a decline in routine […]

FDA Approves Vaccine for Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

October 30, 2023

Category: Industry, Vaccines

On Oct. 20, 2023 Pfizer announced that PENBRAYA, its vaccine for meningococcal groups A, B, C, W, and Y, has been approved by FDA. According to Pfizer, PENBRAYA is the first and only vaccine to protect against the five most […]

Cell and Gene Therapy, Industry

FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours

November 28, 2023


Ogsiveo has been specifically approved for use in adults with progressing desmoid tumours who require systemic treatment. Each year, an estimated 1,650 people in the US are diagnosed with desmoid tumours, which may invade surrounding structures and organs, resulting in […]

FDA, Regulations

FDA approves first therapy for rare type of non-cancerous tumors

November 28, 2023

Via: World Pharma News

The U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype […]

Cell and Gene Therapy, Industry

FDA investigating cancer risk linked to CAR-T cell therapy

November 28, 2023

Via: Biopharma Dive

The Food and Drug Adminsitration is investigating whether CAR-T cell therapies like Novartis’ Kymriah or Gilead’s Yescarta are linked to the risk of new blood cancers after receiving reports of so-called T cell malignancies in people who have received the […]

Mergers and Acquisitions

Merck to buy private biotech Caraway in neuroscience deal

November 21, 2023

Via: Biopharma Dive

Caraway raised a small Series A round of $23 million in 2018, backed by several pharmaceutical venture arms, including Merck’s. At the time, the company went by the name of Rheostat Therapeutics. It rebranded to Caraway one year later, but […]

Cell and Gene Therapy, Industry

Bristol Myers faces FDA delay on cancer cell therapy decision

November 20, 2023

Via: Biopharma Dive

Last month, Bristol Myers delivered unwanted news, telling investors that sales of new drugs it’s counting on this decade will grow more slowly than expected. One of the chief culprits for that guidance shift was Abecma, sales of which dropped […]

Cell and Gene Therapy, Industry

AZ first to AKT finish line, but FDA clears narrow label

November 17, 2023

Via: Pharmaphorum

Capivasertib has been approved as Truqap for use in combination with AZ’s oestrogen receptor antagonist Faslodex (fulvestrant) for adults with hormone receptor (HR)-positive and HER2-negative locally advanced or metastatic breast cancer, but only if they also have PIK3CA, AKT1, or […]